(Q40772658)

English

The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, d

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, d (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

10

object named as

Paul Emery

0 references

Tsutomu Takeuchi

object named as

Tsutomu Takeuchi

4

0 references

Michael E Weinblatt

1

object named as

Michael E Weinblatt

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

author name string

Philip Mease

2

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Eduardo Mysler

3

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Edit Drescher

5

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Alberto Berman

6

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Jun Xing

7

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Moshe Zilberstein

8

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Subhashis Banerjee

9

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

publication date

2 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

67

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

2591-2600

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism.

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Interleukin 6 and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Integrated safety in tocilizumab clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1002%2FART.39249

21 January 2018

Identifiers

10.1002/ART.39249

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

10.1002/ART.39249

0 references

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

2-s2.0-84958092782

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40772658&oldid=1568007082"